硼中子俘获疗法在脑胶质瘤治疗研究中已经取得很大进展，但由于脑胶质瘤的特性以及缺乏与肿瘤高亲和力的掺硼药物，硼中子俘获治疗的效果并不十分理想。此外，难治性垂体腺瘤具有很多与脑胶质瘤相同的特点，硼中子俘获疗法可能具有一定的意义。文章重点介绍硼中子俘获疗法治疗脑胶质瘤的研究现状和治疗难治性垂体腺瘤的可能性。

Clinical study of boron neutron capture therapy (BNCT) for gliomas has progressed rapidly over the past several decades. However, efficacy of BNCT for brain tumors is far from being perfect at present because of the lack of selectivity of the boron carriers and the characteristics of malignant glioma. Moreover, BNCT may have a significant therapeutic effect on refractory pituitary adenomas which have the malignant characters as well as glioma. This paper reviews the current status of BNCT for human liomas and the possibility to treat refractory pituitary adenomas with BNCT.

代从新（1982—），男，河南南阳市人，博士研究生，研究方向为垂体腺瘤的诊治